646P Phase Ib/II study of ompenaclid (RGX-202-01), afirst-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC)

A. Hendifar,D.R. Spigel, A. Basu-Mallick,D. Richards,M. Fakih, J. Boles, M. Gupta, K. Chung,A. Cohn, A. Espinosa, K.C. Hourdequin, K. Johnson, J.M. Michalski, J.G. Misleh, S. Mukkamala,A.S. Paulson, S. Ratnam, S.H. Shao, R. Wasserman, L.S. Rosen

Annals of Oncology（2023）

引用 0|浏览9

暂无评分

关键词

advanced/metastatic colorectal cancer,colorectal cancer,oral inhibitor,bevacizumab,creatine transporter,afirst-in-class,second-line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要